NRx Pharmaceuticals

About

Funding history · 17 rounds · $310.9M total

Headcount over time

Offices

Q&A

What is NRx Pharmaceuticals' primary focus?

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD.

What is the current employee count for NRx Pharmaceuticals?

NRx Pharmaceuticals currently has 11-50 employees.

What was NRx Pharmaceuticals' most recent funding round?

NRx Pharmaceuticals completed a Public Offering in February 2026, raising $20,000,001.

When did NRx Pharmaceuticals go public?

NRx Pharmaceuticals went public on NASDAQ in May 2021.

What is the total amount of funding NRx Pharmaceuticals has raised to date?

NRx Pharmaceuticals has raised a total of $55,335,000 USD.

What is NRx Pharmaceuticals' subsidiary HOPE Therapeutics doing?

In September 2025, NRx Pharmaceuticals' subsidiary HOPE Therapeutics closed the acquisition of Dura Medical, which is an initial acquisition in its planned network of interventional psychiatry clinics.

What is the status of NRx Pharmaceuticals' NRX-100 product?

In September 2025, NRx Pharmaceuticals re-filed an Abbreviated New Drug Application (ANDA) for KETAFREE™, its preservative-free IV Ketamine (NRX-100).

What recent FDA designation did NRx Pharmaceuticals receive for NRX-100?

In August 2025, NRx Pharmaceuticals received FDA Fast Track Designation for NRX-100 for suicidal ideation in patients with depression, including bipolar depression.

What is NRx Pharmaceuticals' current market capitalization?

NRx Pharmaceuticals has a market capitalization of $80,229,957 USD.

Team · 20

Jonathan C. Javitt

Founder · Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics

Daniel C. Javitt

Founder · Co-founder & Chair, Scientific Advisory Board

Michael Abrams

Chief Financial Officer

Rick Panicucci

Chief Manufacturing Officer

Rebecca S. Cohen

Medical Director

Dennis K. McBride

Chief Strategy Officer

Hervé Perron

Chief Scientist

Joshua Brown

Chief Medical Innovation Officer

Glenn D. Tyson

Chief Commercial Officer

Chaim Hurvitz

Director

Patrick Flynn

Audit Committee Chair

Michael Taylor

Chief Development Officer

Janet Rehnquist

Director

Philip T. Lavin

Chief Methodologist

Marion Leboyer

Principal Investigator (EU)

Andrew Nierenberg

Principal Investigator

Wayne Pines

Regulatory & Patient Advocacy Advisor

Dan Iosifescu

Advisor

Gerard Sanacora

Advisor

Joseph M. Casper

Chief Operating Officer

Sectors & technology

Highlights

Tags